PT  - JOURNAL ARTICLE
AU  - Maritsi, Despoina N.
AU  - Vougiouka, Olga
AU  - Eleftheriou, Despina
TI  - Discontinuation of Canakinumab following Clinical Disease Remission Is Feasible in Patients with Systemic Juvenile Idiopathic Arthritis
AID  - 10.3899/jrheum.190011
DP  - 2020 Feb 15
TA  - The Journal of Rheumatology
PG  - jrheum.190011
4099  - http://www.jrheum.org/content/early/2020/02/10/jrheum.190011.short
4100  - http://www.jrheum.org/content/early/2020/02/10/jrheum.190011.full
AB  - The optimal duration of treatment in patients with juvenile idiopathic arthritis, especially systemic JIA (sJIA), is a major concern for parents and physicians alike. Innovative medicines have managed to control this otherwise potentially life-threatening condition1. However, questions remain regarding the duration and the best timing for cessation of treatment.